US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
CA2341409A1
(en)
*
|
1998-08-31 |
2000-03-09 |
Merck And Co., Inc. |
Novel angiogenesis inhibitors
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
SK3842001A3
(en)
*
|
1998-09-18 |
2002-04-04 |
Basf Ag |
Pyrrolopyrimidines as protein kinase inhibitors (revised)
|
US6265403B1
(en)
*
|
1999-01-20 |
2001-07-24 |
Merck & Co., Inc. |
Angiogenesis inhibitors
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
BR0014075A
(pt)
*
|
1999-09-17 |
2002-07-16 |
Abbott Gmbh & Co Kg |
Inibidores de quinase como agentes terapêuticos
|
DE60004685T2
(de)
|
1999-09-17 |
2004-07-29 |
Abbott Gmbh & Co. Kg |
Pyrazolopyrimidine als arzneimittel
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
US7101869B2
(en)
|
1999-11-30 |
2006-09-05 |
Pfizer Inc. |
2,4-diaminopyrimidine compounds useful as immunosuppressants
|
US7369946B2
(en)
|
2000-03-29 |
2008-05-06 |
Abbott Gmbh & Co. Kg |
Method of identifying inhibitors of Tie-2
|
WO2001072778A2
(en)
*
|
2000-03-29 |
2001-10-04 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Method of identifying inhibitors of tie-2
|
AU2000240570A1
(en)
*
|
2000-03-29 |
2001-10-08 |
Knoll Gesellschaft Mit Beschraenkter Haftung |
Pyrrolopyrimidines as tyrosine kinase inhibitors
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
KR100403860B1
(ko)
*
|
2000-12-27 |
2003-11-01 |
엘지전자 주식회사 |
차세대 이동통신 시스템의 접속시도시의 충돌감소를 위한알에이씨에이치 선택방법
|
TWI238824B
(en)
*
|
2001-05-14 |
2005-09-01 |
Novartis Ag |
4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
|
KR100875380B1
(ko)
*
|
2001-06-23 |
2008-12-23 |
아벤티스 파마슈티칼스 인크. |
단백질 키나제 억제제로서의 피롤로피리미딘
|
DE60223063T2
(de)
|
2001-06-29 |
2008-07-17 |
Ab Science |
C-kit inhibitoren
|
PT1401413E
(pt)
|
2001-06-29 |
2007-02-28 |
Ab Science |
Uso de inibidores da tirosina cinase para tratar doenças alérgicas
|
WO2003002107A2
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
|
CA2452390A1
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating bone loss
|
WO2003002109A2
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
ES2266553T3
(es)
|
2001-06-29 |
2007-03-01 |
Ab Science |
Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
|
PT1401416E
(pt)
|
2001-06-29 |
2007-02-28 |
Ab Science |
Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
|
GB0121033D0
(en)
*
|
2001-08-30 |
2001-10-24 |
Novartis Ag |
Organic compounds
|
WO2003022852A2
(en)
*
|
2001-09-11 |
2003-03-20 |
Smithkline Beecham Corporation |
Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
|
US20030225273A1
(en)
*
|
2002-03-21 |
2003-12-04 |
Michaelides Michael R. |
Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
|
US20030199525A1
(en)
*
|
2002-03-21 |
2003-10-23 |
Hirst Gavin C. |
Kinase inhibitors
|
BR0313078A
(pt)
|
2002-08-06 |
2005-07-12 |
Astrazeneca Ab |
Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou de um sal deste farmaceuticamente aceitável
|
UA80171C2
(en)
*
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
WO2004100868A2
(en)
*
|
2003-04-23 |
2004-11-25 |
Abbott Laboratories |
Method of treating transplant rejection
|
JP2006528685A
(ja)
*
|
2003-05-06 |
2006-12-21 |
スミスクライン ビーチャム コーポレーション |
新規化合物
|
US7429596B2
(en)
*
|
2003-06-20 |
2008-09-30 |
The Regents Of The University Of California |
1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
|
AR045037A1
(es)
|
2003-07-10 |
2005-10-12 |
Aventis Pharma Sa |
Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
|
CA2546192C
(en)
*
|
2003-11-17 |
2010-04-06 |
Pfizer Products Inc. |
Pyrrolopyrimidine compounds useful in treatment of cancer
|
US20060025383A1
(en)
*
|
2004-02-03 |
2006-02-02 |
Neil Wishart |
Aminobenzoxazoles as therapeutic agents
|
GB0403606D0
(en)
*
|
2004-02-18 |
2004-03-24 |
Novartis Ag |
Organic compounds
|
EP1773836B1
(en)
*
|
2004-05-27 |
2012-09-05 |
Pfizer Products Inc. |
Pyrrolopyrimidine derivatives useful in cancer treatment
|
EP1831225A2
(en)
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
CA2601766A1
(en)
*
|
2005-03-17 |
2006-09-28 |
Novartis Ag |
N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
|
NZ567133A
(en)
*
|
2005-09-30 |
2011-07-29 |
Vertex Pharma |
Deazapurines useful as inhibitors of janus kinases
|
CN102936250B
(zh)
*
|
2005-11-17 |
2014-07-09 |
Osi医药有限责任公司 |
稠合双环mTOR抑制剂
|
US20070135387A1
(en)
*
|
2005-12-08 |
2007-06-14 |
Michaelides Michael R |
Inhibitors of protein kinases
|
JP5156644B2
(ja)
*
|
2006-01-25 |
2013-03-06 |
オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー |
不飽和mTOR阻害剤
|
JP5430943B2
(ja)
*
|
2006-01-25 |
2014-03-05 |
シンタ ファーマシューティカルズ コーポレーション |
炎症及び免疫関連用途のための置換芳香族化合物
|
KR101499783B1
(ko)
|
2006-04-04 |
2015-03-09 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
키나제 길항물질
|
CL2007002617A1
(es)
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
ES2584331T3
(es)
|
2006-09-22 |
2016-09-27 |
Pharmacyclics Llc |
Inhibidores de tirosina cinasa de Bruton
|
EP1969934A1
(de)
*
|
2007-03-12 |
2008-09-17 |
Bayer CropScience AG |
4-Cycloalkyl-oder 4-arylsubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide
|
US20120101113A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
BRPI0810086B1
(pt)
*
|
2007-03-28 |
2021-11-09 |
Pharmacyclics Llc |
Composto inibidor de tirosina quinase de bruton, uso do referido composto e composição farmacêutica
|
WO2009046448A1
(en)
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
KR101653842B1
(ko)
|
2008-01-04 |
2016-09-02 |
인텔리카인, 엘엘씨 |
특정 화학 물질, 조성물 및 방법
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
JP5547099B2
(ja)
|
2008-03-14 |
2014-07-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤および使用方法
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
WO2009117482A1
(en)
*
|
2008-03-19 |
2009-09-24 |
Osi Pharmaceuticals, Inc |
Mtor inhibitor salt forms
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
NZ590258A
(en)
|
2008-07-08 |
2013-10-25 |
Intellikine Llc |
Kinase inhibitors and methods of use
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
CA2740885C
(en)
*
|
2008-10-16 |
2018-04-03 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
US7718662B1
(en)
*
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
CA2799579A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
SG186077A1
(en)
|
2010-06-03 |
2013-01-30 |
Pharmacyclics Inc |
The use of inhibitors of bruton's tyrosine kinase (btk)
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
複素環化合物及びその使用
|
CN103648499B
(zh)
|
2011-01-10 |
2017-02-15 |
无限药品股份有限公司 |
用于制备异喹啉酮的方法及异喹啉酮的固体形式
|
FR2970967B1
(fr)
*
|
2011-01-27 |
2013-02-15 |
Pf Medicament |
Derives de type azaindazole ou diazaindazole comme medicament
|
CN103491962B
(zh)
|
2011-02-23 |
2016-10-12 |
因特利凯有限责任公司 |
激酶抑制剂的组合及其用途
|
CN103534257A
(zh)
*
|
2011-04-05 |
2014-01-22 |
辉瑞有限公司 |
作为原肌球蛋白相关激酶抑制剂的吡咯并[2,3-d]嘧啶衍生物
|
EA201490265A1
(ru)
|
2011-07-13 |
2014-12-30 |
Фармасайкликс, Инк. |
Ингибиторы тирозинкиназы брутона
|
TWI565709B
(zh)
|
2011-07-19 |
2017-01-11 |
英菲尼提製藥股份有限公司 |
雜環化合物及其用途
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
EP2751093A1
(en)
|
2011-08-29 |
2014-07-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2846496C
(en)
|
2011-09-02 |
2020-07-14 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US9687488B2
(en)
|
2012-05-03 |
2017-06-27 |
St. Louis College Of Pharmacy |
Compositions and methods for increasing neurotrophic peptides
|
UA114421C2
(uk)
|
2012-06-04 |
2017-06-12 |
Фармасайклікс Ллс |
Кристалічна форма інгібітору тирозинкінази брутона
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
JP6575950B2
(ja)
|
2012-07-24 |
2019-09-18 |
ファーマサイクリックス エルエルシー |
Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異
|
EP2689778A1
(en)
*
|
2012-07-27 |
2014-01-29 |
Pierre Fabre Medicament |
Derivatives of azaindoles or diazaindoles for treating pain
|
JP2015532287A
(ja)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ire1の調節
|
SG11201503842PA
(en)
|
2012-11-15 |
2015-06-29 |
Pharmacyclics Inc |
Pyrrolopyrimidine compounds as kinase inhibitors
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
CN103333096A
(zh)
*
|
2013-06-25 |
2013-10-02 |
苏州大学 |
一种化学选择性制备多功能吡咯衍生物的新方法
|
SG11201602421VA
(en)
|
2013-09-30 |
2016-04-28 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
BR112016007467B1
(pt)
|
2013-10-04 |
2022-09-20 |
Infinity Pharmaceuticals, Inc |
Compostos heterocíclicos e usos dos mesmos
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CN106456628A
(zh)
|
2014-03-19 |
2017-02-22 |
无限药品股份有限公司 |
用于治疗PI3K‑γ介导的障碍的杂环化合物
|
JP2017509336A
(ja)
|
2014-03-20 |
2017-04-06 |
ファーマサイクリックス エルエルシー |
ホスホリパーゼcガンマ2及び耐性に関連した変異
|
US20150320755A1
(en)
|
2014-04-16 |
2015-11-12 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
AU2015296215A1
(en)
|
2014-08-01 |
2017-03-23 |
Pharmacyclics Llc |
Inhibitors of bruton's tyrosine kinase
|
MX2017001671A
(es)
|
2014-08-07 |
2017-07-04 |
Pharmacyclics Llc |
Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
CA2976695C
(en)
|
2015-03-03 |
2023-02-07 |
Pharmacyclics Llc |
Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
|
US10550124B2
(en)
|
2015-08-13 |
2020-02-04 |
San Diego State University Foundation |
Atropisomerism for increased kinase inhibitor selectivity
|
MX2018003058A
(es)
|
2015-09-14 |
2018-08-01 |
Infinity Pharmaceuticals Inc |
Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
ES2964781T3
(es)
*
|
2016-06-21 |
2024-04-09 |
Nerviano Medical Sciences Srl |
Derivados de sulfonamida n-fenilsustituida como inhibidores de la cinasa
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
PL3612519T3
(pl)
|
2017-04-18 |
2022-05-02 |
Eli Lilly And Company |
Związki fenylo-2-hydroksy-acetyloamino-2-metylo-fenylowe
|
WO2020038405A1
(zh)
*
|
2018-08-22 |
2020-02-27 |
江苏恒瑞医药股份有限公司 |
一种吡咯并氨基哒嗪酮化合物的制备方法及其中间体
|
KR20220021462A
(ko)
*
|
2019-04-10 |
2022-02-22 |
셀레스티아 바이오테크 아게 |
Notch 신호 전달 경로의 억제제 및 암의 치료에서 이의 용도
|
CN114126620A
(zh)
*
|
2019-05-13 |
2022-03-01 |
传达治疗有限公司 |
Fgfr抑制剂和其使用方法
|
CN110483523B
(zh)
*
|
2019-08-27 |
2022-11-22 |
药雅科技(上海)有限公司 |
一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
|
BR112022003584A2
(pt)
*
|
2019-08-29 |
2022-05-24 |
Hibercell Inc |
Compostos de pirrolopirimidina inibidores de perk
|
WO2021038540A1
(en)
|
2019-08-31 |
2021-03-04 |
Sun Pharma Advanced Research Company Limited |
Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
|
AU2020436612A1
(en)
|
2020-03-16 |
2022-09-01 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
TW202233625A
(zh)
*
|
2020-11-18 |
2022-09-01 |
美商傳達治療有限公司 |
Fgfr抑制劑及其製造及使用方法
|
KR20230121758A
(ko)
|
2020-11-18 |
2023-08-21 |
데시페라 파마슈티칼스, 엘엘씨. |
Gcn2 및 perk 키나제 억제제 및 그의 사용 방법
|
CA3231948A1
(en)
*
|
2021-09-23 |
2023-03-30 |
Jingyu Hu |
Fgfr inhibitors and methods of use thereof
|
WO2023104035A1
(zh)
*
|
2021-12-06 |
2023-06-15 |
英矽智能科技(上海)有限公司 |
取代的单环或双环杂环化合物,其制法与医药上的用途
|
WO2023202625A1
(zh)
*
|
2022-04-20 |
2023-10-26 |
深圳福沃药业有限公司 |
Fgfr2抑制剂及使用方法
|